Press Releases May 13, 2026 08:00 AM

Cerence AI to Participate in TD Cowen 54th Annual Technology, Media & Telecom Conference

Cerence Inc. announces participation in TD Cowen's 54th Annual Technology, Media & Telecom Conference

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
CRNC

Cerence Inc., a leader in conversational AI-powered automotive experiences, announced its participation in the TD Cowen 54th Annual Technology, Media & Telecom Conference. Its CEO and CFO will engage in a fireside chat and one-on-one investor meetings, highlighting company strategies and innovations in AI and automotive technology.

Cerence AI to Participate in TD Cowen 54th Annual Technology, Media & Telecom Conference
CRNC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Cerence will present at the TD Cowen Annual Technology, Media & Telecom Conference, reflecting ongoing investor engagement.
  • The company focuses on AI-driven automotive user experiences, integrating voice, generative AI, and large language models.
  • Cerence has significant market impact with technology shipped in over 525 million vehicles, partnering with leading OEMs and tech firms.

BURLINGTON, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced that the Company will participate in the TD Cowen 54th Annual Technology, Media & Telecom Conference in New York City.

Cerence AI’s President and Chief Executive Officer, Brian Krzanich, and its Chief Financial Officer, Tony Rodriquez, will participate in a fireside chat on Wednesday, May 27 at 9:05 am ET. A live webcast will be available on the Company’s website at www.cerence.ai under the “Investors” section. A replay of the webcast will be available for 90 days after the event.

The Company also will conduct one-on-one meetings with investors throughout the day. To schedule a meeting, please contact your TD Cowen representative, or Cerence AI Investor Relations at cerence@pondel.com.

To learn more about Cerence AI, visit www.cerence.ai, and follow the company on LinkedIn.

About Cerence Inc.
Cerence Inc. (NASDAQ: CRNC) is a global industry leader in creating intuitive, seamless, AI-powered experiences across automotive and transportation. Leveraging decades of innovation and expertise in voice, generative AI, and large language models, Cerence powers integrated experiences that create safer, more connected, and more enjoyable journeys for drivers and passengers alike. With more than 525 million cars shipped with Cerence technology, the company partners with leading automakers, transportation OEMs, and technology companies to advance the next generation of user experiences. Cerence is headquartered in Burlington, Massachusetts, with operations globally and a worldwide team dedicated to pushing the boundaries of AI innovation. For more information, visit www.cerence.ai.

Contact Information
For Media: press@cerence.com
For Investors: cerence@pondel.com 


Risks

  • Market adoption and competition in the rapidly evolving conversational AI and automotive tech sectors may impact growth.
  • Uncertainty in global automotive industry demand and supply chain challenges could affect Cerence's business performance.
  • Reliance on partnerships with automakers and technology companies introduces dependency risks related to collaboration and contract renewals.

More from Press Releases

Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromegaly Control Jun 14, 2026 Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026